- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02987374
Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization (SLVP023)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is an exploratory study using a strategy that has not been previously employed to investigate B-cell responses. Investigators will collect blood samples from the volunteers at a higher frequency than in the two previous flu seasons to better define the dynamic response to vaccination. The objective is to compare the Ig gene repertoire before and after vaccination by deep sequencing PBMC and proteomic analysis of antibody CDR3 regions at 10 different time points before and after immunization.
This is a Phase IV study of healthy adults who are given standard TIV off-season. There are no exclusions for gender, ethnicity or race. Following confirmation of written informed consent, baseline blood samples will be drawn from all study participants at Day -5, Day -3 and Day 0 prior to immunization, and at Days 1, 4, 7, 9, 11, 28 and 180 post-immunization. Volunteers will be vaccine-naïve for the 2010-2011 and 2011-2012 seasonal influenza vaccines. All participants will receive a single dose of the current seasonal influenza vaccine by intramuscular (IM) injection at Day 0.
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Otherwise healthy, 18-30 year old young adult.
- Availability for follow-up for the planned duration of the study at least 180 days after immunization.
- Acceptable medical history by medical history and vital signs.
Exclusion Criteria:
- Prior vaccination with 2010-2011 seasonal TIV or LAIV.
- Prior off-study vaccination with the current 2011-2012 seasonal TIV or LAIV
- Weight less than 110 pounds.
- Allergy to egg or egg products, or to vaccine components, including gelatin or thimerosal (thimerosal in TIV multidose vials only).
- Life-threatening reactions to previous influenza vaccinations
- Active systemic or serious concurrent illness, including febrile illness on the day of vaccination
- History of immunodeficiency (including HIV infection)
- Known or suspected impairment of immunologic function, including, but not limited to, clinically significant liver disease, diabetes mellitus treated with insulin, moderate to severe renal disease, or any other chronic disorder which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol.
- Blood pressure >150 systolic or >95 diastolic at first study visit
- Hospitalization in the past year for congestive heart failure or emphysema.
- Chronic Hepatitis B or C.
- Recent or current use of immunosuppressive medication, including systemic glucocorticoids. Corticosteroid nasal sprays and topical steroids are permissible.
- Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors such as breast cancer or prostate cancer with recurrence in the past year, and any hematologic cancer such as leukemia).
- Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol.
- History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year.
- Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be reviewed by investigator to determine if this would affect the volunteer's safety.
- Receipt of blood or blood products within the past 6 months.
- Medical or psychiatric condition or occupational responsibilities that preclude participant compliance with the protocol
- Receipt of inactivated vaccine 14 days prior to study enrollment, planned vaccinations prior to completion of Visit 09 (Day 28 after study vaccination), or planned vaccination 14 days prior to Visit 10 (6 months after study vaccination).
- Receipt of live, attenuated vaccine 60 days prior to study enrollment, planned vaccination prior to completion of Visit 09 (Day 28 after study vaccination), or planned vaccination 14 days prior to Visit 10 (6 months after study vaccination).
- History of Guillain-Barré Syndrome
- Pregnant or lactating woman
- Use of investigational agents within 30 days prior to study enrollment or planned use during the study period.
- Donation of the equivalent of a unit of blood within 6 weeks prior to study enrollment, or during the first 5 weeks of study participation.
- A member of the study team or their family member, to include investigators, research laboratory staff, clinical research staff.
- Any condition which, in the opinion of the investigator, might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Autre: 2011-2012 Fluzone IIV3 (IM)
Seasonal trivalent flu vaccine: NDC No 49281-011-50
|
2011-2012 Fluzone IIV3 vaccine delivered intramuscularly (IM)
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Number of Participants Who Received Influenza Vaccine
Délai: Day 0 to 180 post-immunization
|
Day 0 to 180 post-immunization
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Number of Participants With Related Adverse Events
Délai: Day 0 to 180 post-immunization
|
Day 0 to 180 post-immunization
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Proteomic Analysis of Antibody CDR3 Regions at 10 Different Time Points Before and After Immunization.
Délai: Day -5 to 180 post-immunization
|
Proteomic analysis: Identification, production, and characterization of Influenza A specific antibodies and their CDRH3 amino-acid sequences.
|
Day -5 to 180 post-immunization
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Lee J, Boutz DR, Chromikova V, Joyce MG, Vollmers C, Leung K, Horton AP, DeKosky BJ, Lee CH, Lavinder JJ, Murrin EM, Chrysostomou C, Hoi KH, Tsybovsky Y, Thomas PV, Druz A, Zhang B, Zhang Y, Wang L, Kong WP, Park D, Popova LI, Dekker CL, Davis MM, Carter CE, Ross TM, Ellington AD, Wilson PC, Marcotte EM, Mascola JR, Ippolito GC, Krammer F, Quake SR, Kwong PD, Georgiou G. Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nat Med. 2016 Dec;22(12):1456-1464. doi: 10.1038/nm.4224. Epub 2016 Nov 7.
- Horns F, Vollmers C, Dekker CL, Quake SR. Signatures of selection in the human antibody repertoire: Selective sweeps, competing subclones, and neutral drift. Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1261-1266. doi: 10.1073/pnas.1814213116. Epub 2019 Jan 8.
- de Bourcy CF, Angel CJ, Vollmers C, Dekker CL, Davis MM, Quake SR. Phylogenetic analysis of the human antibody repertoire reveals quantitative signatures of immune senescence and aging. Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1105-1110. doi: 10.1073/pnas.1617959114. Epub 2017 Jan 17.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SU-24167
- U19AI057229-06 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Grippe
-
Mitsubishi Tanabe Pharma CorporationComplété
-
Jiangsu Province Centers for Disease Control and...Royal (Wuxi) Biological Co., LTDComplétéGroupe A, C Méningite polysaccharidique | Haemophilus Influenza de type bChine
-
Jiangsu Province Centers for Disease Control and...Chengdu Olymvax Biopharmaceuticals Inc.Complété
-
University Hospital, LilleCSL Behring; Laboratoire français de Fractionnement et de Biotechnologies; O... et autres collaborateursRésiliéInfections pneumococciques | Pneumonie bactérienne | Méningite bactérienne | Otite moyenne | Infection chronique des sinus | Infection streptococcique | Déficit en anticorps | Carence en complément | Infections à Neisseria | Haemophilus InfluenzaFrance
-
QIAGEN Gaithersburg, IncComplétéInfections par le virus respiratoire syncytial | Grippe A | Rhinovirus | Grippe B | Panneau avancé QIAGEN ResPlex II | Infection due au virus parainfluenza humain 1 | Parainfluenza de type 2 | Parainfluenza de type 3 | Parainfluenza de type 4 | Métapneumovirus humain A/B | Virus/échovirus Coxsackie | Adénovirus... et d'autres conditionsÉtats-Unis
Essais cliniques sur 2011-2012 Fluzone IIV3 (IM)
-
Addpharma Inc.ComplétéHypertension | HyperlipidémiesCorée, République de
-
Sanofi Pasteur, a Sanofi CompanyComplété
-
Children's Hospital Medical Center, CincinnatiComplétéDystrophie musculaire de Duchenne | Atrophie musculaire spinale | Dystrophie musculaire congénitale
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Complété
-
International Vaccine InstituteComplétéEn bonne santéCorée, République de
-
PharmaJet, Inc.Complété
-
Crucell Holland BVComplété
-
Tampere UniversityFinnish Cultural Foundation; Sigrid Jusélius Foundation; Päivikki and Sakari... et autres collaborateursRecrutementInsuffisance rénale | Sténose aortique | Hypertension primaire | Hypertension secondaireFinlande